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Robert W. Chang7. 1University of California, San
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Objectives: There is considerable controversy
regarding the signiﬁcance and appropriate treatment of
type II endoleaks (T2L) after EVAR. We report our
long-term experience with T2L management in a large
multicenter registry.
Methods: Between 2000 and 2010, 1736 patients un-
derwent EVAR. The incidence of T2L was observed. Pri-
mary outcomes were mortality and aneurysm-related
mortality (ARM). Secondary outcomes were change in
aneurysm sac size and reintervention.
Results: During the median follow-up of 32.2 months
(interquartile range, 14.2-52.8 months), there were 474
T2L (27.3%). There were no late abdominal aortic aneurysm
ruptures attributable to a T2L. Patients with T2L had no dif-
ference in overall mortality (P ¼ .47) or ARM (P ¼ .26)
compared with those without T2L. A median sac growth
of 5 mm (interquartile range, 2-10 mm) was seen in 46.1%
of patients with T2L. Of these, 11.0% had an additional
type of endoleak. Reintervention occurred in 111 (23.4%)
of all patients with T2L, of which 74%were performed in pa-
tients with sac growth, and was technically successful in
31.5% of cases. Thirty-nine patients (35.1%) underwent lum-
bar embolization, 31 (27.9%) had adjunctive stents placed, 7
(6.3%) had open surgical revision, and 3 (2.7%) had direct sac
injection. Thirty-one patients (27.9%) hadmultiple interven-
tions. After excluding patients with other types of endoleak,
patients with T2L-associated sac growth had no difference in
overall mortality (P ¼ .57) or ARM (P ¼ .09), with or
without reintervention.
Conclusions: In our multicenter EVAR registry, over-
all mortality and ARM were unaffected by the presence of a
T2L. Moreover, patients who were simply observed for
T2L-associated sac growth had similar outcomes as those
who underwent reintervention for the same, suggesting
that concomitant other endoleak types may be the primary
driver of mortality. Our future work will investigate the
most cost-effective ways to select patients for intervention
besides sac growth alone.
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Objectives: To evaluate the implications of thoracic and
abdominal aortic false lumen embolization (FLE) during
thoracic endovascular aortic repair (TEVAR) and endovascu-
lar aneurysm repair (EVAR) for complicated aortic dissections.
Methods: Ninety-six consecutive patients who pre-
sented with complicated acute and chronic type B thoracic
aortic dissections (TAD) who underwent TEVAR with FLE
(n ¼ 32 [33.3%]) and without FLE (n ¼ 52 [54.2%]), as
well as abdominal aortic dissections (AAD) who underwent
EVAR with FLE (n ¼ 4 [4.2%]) and without FLE (n ¼ 8
[8.3%]). In a subset of 26 patients, before FLE, a wireless
cardioMEMS Endosure pressure sensor was placed in the
false lumen and used to quantify the false lumen to systemic
systolic, diastolic, mean, pulse pressure indices. All data
were prospectively collected and outcomes analyzed.
Results: The 30-day mortality in patients with FLE
(n¼ 1 [2.3%]) was signiﬁcantly lower than patients without
FLE (n ¼ 5 [9.6%]), and none of the patients with FLE
developed spinal cord ischemia. After TEVAR and FLE,
nine patients (29.0%) had persistent retrograde false lumen
endoleaks that required repeat embolization procedures.
FLE and complete thrombosis was achieved in 100% of
EVAR patients. At a mean 18-month follow-up, 88% (23
of 26 patients) had a signiﬁcant decrease in all false lumen-
to-systemic pressure indices, and 65% (17 of 26 patients)
had a false lumen remodeling with>5 mmmaximum diam-
eter reduction. At midterm follow-up, there are no thoracic
or abdominal related ruptures, conversions, or deaths.
Conclusions: FLE during TEVAR for complicated
acute and chronic TAD and AAD is associated with a lower
mortality and is effective in reducing false lumen pressures
and maximum diameter. This adjunctive technique should
be consideredwhenmanaging complicated aortic dissections.
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ciety for Vascular Surgery (SVS) wound, ischemia, and foot
infection (WIfI) classiﬁcation system correlates with impor-
tant clinical outcomes for limb salvage and wound healing.
Methods: We analyzed 201 consecutive patients with
threatened limbs treated from 2010 to 2011 in an aca-
demic center. We stratiﬁed patients into clinical stages 1
to 4 based on the SVS WIfI classiﬁcation. We compared
the SVS objective performance goals of major amputation,
1-year amputation-free survival rate (AFS), and wound
healing time (WHT) according to WIfI clinical stages.
Results: Patients were a mean age of 59 years, 79%
were men, and 86% had diabetes. Forty-two patients
(21%) required major amputation, and 159 (78%) had
limb salvage. The amputation group had a signiﬁcantly
higher prevalence of advanced stage 4 patients (P <
.001), whereas the limb salvage group presented predomi-
nantly as stages 1 to 3. Patients in clinical stages 3 and 4
had a signiﬁcantly higher incidence of amputation (P <
.001), decreased AFS (P < .001), and delayed WHT
(P < .001) compared with those in stages 1 and 2. Among
patients presenting with stage 3, primarily as a result of
wound and ischemia, revascularization resulted in acceler-
ated WHT (P ¼ .008).
Conclusions: These data support the underlying
concept of the SVS WIfI classiﬁcation. As the clinical stage
progresses, the risk of major amputation increases, 1-year
AFS declines, and time to wound healing is prolonged.
We further demonstrated beneﬁt of revascularization to
improve WHT in selected patients, especially those in stage
3. Future efforts are warranted to incorporate the SVS
WIfI classiﬁcation into clinical decision-making algorithms
in conjunction with a comorbidity index and anatomic
classiﬁcation.
Table.
Amputation, 1-year AFS, Mean WHT (95% CI),
Stage No. % (n) % (n) (days)1 39 0 (0) 100 (39) 94 (69-119)
2 50 0 (0) 100 (50) 115 (92-138)
3 53 8 (4) 92 (49) 162 (105-220)
4 59 64 (38) 63 (38) 263 (167-360)AFS, Amputation-free survival; CI, conﬁdence interval; WHT, wound
healing time.
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Objectives: Endovascular aneurysm repair (EVAR) is
now a mainstay of therapy for abdominal aortic aneurysm,
although it remains associated with signiﬁcant expense. We
performed a comprehensive analysis of EVAR delivery at an
academic medical center to identify targets for qualityimprovement and cost reduction in light of impending
health care reform.
Methods: All infrarenal EVARs performed from April
2011 to March 2012 were identiﬁed (n ¼ 127). Proce-
dures were included if they met standard commercial in-
structions for use guidelines, used a single manufacturer,
and were billed to Medicare Diagnosis-Related Group
238 (n ¼ 49). Using DMAIC (deﬁne, measure, analyze,
improve, control) quality improvement methodology, tar-
gets for EVAR quality improvement were identiﬁed, and
high-yield changes were implemented. Procedure technical
costs were calculated before and after process redesign.
Results: Perioperative services and clinic visits were
identiﬁed as targets for quality improvement efforts and
cost reduction. Mean technical costs before the interven-
tion were $31,672, with endograft implants accounting
for 52%. Pricing redesign in collaboration with hospital
purchasing reduced mean EVAR technical costs to
$28,607, a 10% reduction in overall cost, with endograft
implants now accounting for 46%. Perioperative implemen-
tation of instrument tray redesign reduced instrument use
by 32% (184 vs 132 instruments), saving $50,000 annually.
Unnecessary clinic visits were reduced by 39% (1.6 vs 1.1
clinic visits per patient) through implementation of a pre-
clinic imaging protocol. There was no difference in mean
length of stay after the intervention (2.85 vs 2.45 days,
P ¼ NS).
Conclusions: Comprehensive EVAR delivery redesign
leads to cost reduction and waste elimination, while preser-
ving quality. Future efforts aimed to achieve more compet-
itive and transparent device pricing will make EVAR more
cost neutral and enhance its ﬁnancial sustainability for
healthcare systems.
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Objectives: To prospectively evaluate the neurologic
status of all patients undergoing carotid revascularization
in a single institution during a 6-year period.
Methods: Between January 2007 and June 2013, all
patients undergoing carotid revascularization underwent in-
dependent neurologic evaluation preprocedure, postproce-
dure, and at 30 days. Symptom status (symptomatic vs
asymptomatic), participation in clinical trials, stroke, death,
andmyocardial infarction (MI)were independently reviewed.
c2 Analysis and the Fisher exact test were performed.
Results: A total of 2301 interventions were per-
formed: 1969 carotid endarterectomies (CEA) 85.6% and
332 carotid angioplasty and stent procedures (CAS)
14.4%. Stroke/death/MI was 5.0%. Of 1814 patients,
